Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Autoimmune hemolytic anemia

3

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Tyrosine-protein kinase SYK

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2018

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Rigel Pharmaceuticals

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

EPA CompTox

3

FDA UNII

3

MERCK INDEX

3

NCI_THESAURUS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHEMORRHAGICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

VITAMIN K AND OTHER HEMOSTATICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other systemic hemostatics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FOSTAMATINIB

SQ8A3S5101

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase SYK

Conditions:

Rheumatoid arthritis

Immune thrombocytopenia

Autoimmune hemolytic anemia

IgA nephropathy

Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpur...

a, however, AstraZeneca decided not to proceed with regulatory filings and return the rights to the compound to Rigel Pharmaceuticals. In 2018 the drug was approved by the FDA for treatment of chronic immune thrombocytopenia. Fostamatinib is being developed for Autoimmune Hemolytic Anemia (phase II), graft versus host disease (phase I) and ovarian cancer (phase I).

FOSTAMATINIB DISODIUM ANHYDROUS

X9417132K8

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase SYK

Conditions:

Rheumatoid arthritis

Immune thrombocytopenia

Autoimmune hemolytic anemia

IgA nephropathy

Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpur...

a, however, AstraZeneca decided not to proceed with regulatory filings and return the rights to the compound to Rigel Pharmaceuticals. In 2018 the drug was approved by the FDA for treatment of chronic immune thrombocytopenia. Fostamatinib is being developed for Autoimmune Hemolytic Anemia (phase II), graft versus host disease (phase I) and ovarian cancer (phase I).

FOSTAMATINIB DISODIUM

86EEZ49YVB

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase SYK

Conditions:

Rheumatoid arthritis

Immune thrombocytopenia

Autoimmune hemolytic anemia

IgA nephropathy

Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpur...

a, however, AstraZeneca decided not to proceed with regulatory filings and return the rights to the compound to Rigel Pharmaceuticals. In 2018 the drug was approved by the FDA for treatment of chronic immune thrombocytopenia. Fostamatinib is being developed for Autoimmune Hemolytic Anemia (phase II), graft versus host disease (phase I) and ovarian cancer (phase I).

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1